Weiwei Li
9Patents
4h-index
22Co-inventors
53Inventor score
Filing activity: Feb 10, 2005 → Aug 19, 2020
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US9486512B2 | In situ antigen-generating cancer vaccine | Human Necessities | 30 | Active |
| US7465705B2 | Nogo receptor antagonists | Emerging Cross-Sectional Technologies | 22 | Expired |
| US9937249B2 | Mesoporous silica compositions for modulating immune responses | Emerging Cross-Sectional Technologies | 15 | Active |
| US8772318B2 | Methods and compositions related to targeting monoacylglycerol lipase | Chemistry; Metallurgy | 6 | Active |
| US10406216B2 | In situ antigen-generating cancer vaccine | Human Necessities | 4 | Active |
| US11278604B2 | Mesoporous silica compositions comprising inflammatory cytokines comprising inflammatory cytokines for modulating immune responses | Emerging Cross-Sectional Technologies | 1 | Active |
| US8030456B2 | Nogo receptor antagonists | Emerging Cross-Sectional Technologies | 0 | Active |
| US10647959B2 | Cell-friendly inverse opal hydrogels for cell encapsulation, drug and protein delivery, and functional nanoparticle encapsulation | Chemistry; Metallurgy | 0 | Active |
| US12029776B2 | Composition for treating cancer and use and medicament thereof | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.